Melbourne, Australia; 8 April 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). [Read more…]
40 Pro Athletes Who Have Had Stem Cell Treatments
More and more athletes are turning to stem cell treatments, because the pressure to get back on the field is high and access to these experimental therapies is continuing to increase. Athletes commonly suffer serious injuries that could potentially end their careers and cause them serious long-term health complications. Most of them turn to surgery to resolve those injuries.
However, some of them are pursuing stem cell treatments and regenerative therapies, because these procedures are less invasive than surgery and have the potential to speed and augment repair. While the effectiveness of these surgeries is largely unknown, what is clear is that a growing number of athletes are turning to this approach. [Read more…]
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024-
-Marks the first IND for Aruna’s platform with plans to expand AB126, an unmodified exosome derived from proprietary neural stem cells, to other neurological indications including amyotrophic lateral sclerosis-
-Proprietary in-house GMP production capabilities enable scalable, reproducible production of clinical-grade exosomes with high purity and uniformity; analytical methods and well-characterized assays established to ensure therapeutic consistency-
Cryo-Cell to Spin-off Celle Corp., Its Subsidiary Holding Assets Not Directly Associated with Recurring Revenue from Biopreservation
Celle Corp. holds certain assets of Cryo-Cell not directly associated with its recurring revenue derived from privately banked cord blood specimens.
OLDSMAR, Fla.–Cryo-Cell International, Inc. (NYSE American LLC: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company. There is no assurance that such a transaction will take place. [Read more…]
Fiocruz and Caring Cross To Offer Drastically More Affordable CAR-T Therapy in Brazil and Latin America
Local production will permit CAR-T treatment to be available free of charge to patients.
The cost to the Brazilian public health system will be slashed to 10% of the amount currently charged in Europe and the USA (only US$35,000 per dose).
RIO DE JANEIRO and GAITHERSBURG, Md., March 26, 2024 — Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government’s Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection. [Read more…]